Fennec Pharmaceuticals
FENC
63 hedge funds and large institutions have $74.6M invested in Fennec Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 27 increasing their positions, 15 reducing their positions, and 8 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
80% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 15
2.01% more ownership
Funds ownership: 52.56% → 54.57% (+2%)
2% less funds holding
Funds holding: 64 → 63 (-1)
13% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 8
15% less capital invested
Capital invested by funds: $87.7M → $74.6M (-$13.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Solas Capital Management
Darien,
Connecticut
|
+$3.38M |
| 2 |
AACP
Advantage Alpha Capital Partners
San Francisco,
California
|
+$306K |
| 3 |
Morgan Stanley
New York
|
+$268K |
| 4 |
LPC
Lion Point Capital
New York
|
+$260K |
| 5 |
BlackRock
New York
|
+$244K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
DG Capital Management
New York
|
-$651K |
| 2 |
Millennium Management
New York
|
-$319K |
| 3 |
GJL
Gendell Jeffrey L
|
-$298K |
| 4 |
CIBC World Market
Toronto,
Ontario, Canada
|
-$176K |
| 5 |
HIM
Hillsdale Investment Management
Toronto,
Ontario, Canada
|
-$150K |
FENC Hedge Fund Activity: Q3 2024 in Review
63 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Fennec Pharmaceuticals (FENC) for Q3 2024, worth a combined $74.6M — down 15% from $87.7M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of FENC and 7 opened new positions — a net loss of 1 holder — while 15 trimmed existing stakes and 27 added.
The largest buyer was Solas Capital Management, adding an estimated $3.38M. The largest seller was DG Capital Management, cutting an estimated $651K.
- 63 institutional investors held Fennec Pharmaceuticals (FENC) as of Q3 2024, down from 64 in Q2 2024.
- Funds reported $74.6M of Fennec Pharmaceuticals stock for Q3 2024, down 15% quarter-over-quarter.
- 7 funds opened new Fennec Pharmaceuticals positions in Q3 2024 and 8 closed out, a net change of -1 holder.
- The largest Fennec Pharmaceuticals buyer in Q3 2024 was Solas Capital Management, an estimated $3.38M added.
- The largest Fennec Pharmaceuticals seller in Q3 2024 was DG Capital Management, an estimated $651K sold.
Based on aggregated 13F filings for Q3 2024.